Kyushu University Confirms HORIUCHI L-FUCOIDAN Inhibits Binding between ACE2 and Virus Spike Protein (Derived from COVID-19)

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Kyushu University Confirms HORIUCHI L-FUCOIDAN Inhibits Binding between ACE2 and Virus Spike Protein (Derived from COVID-19)

PR Newswire

KURUME, Japan, Feb. 26, 2021 /PRNewswire/ -- FCC Horiuchi Co., Ltd. based in Kurume City, Fukuoka Prefecture, western Japan, has conducted an experiment in inhibiting binding between ACE2 and virus spike protein using HORIUCHI L-FUCOIDAN, manufactured by the company, in collaboration with a graduate school of Kyushu University (Associate Professor Kuniyoshi Shimizu of Division of Sustainable Bioresources Science, Department of Agro-Environmental Sciences, Faculty of Agriculture).

Angiotensin Converting Enzyme II (ACE2) provides a foothold when COVID-19 and SARS viruses enter human cells. If the binding of viral spike protein to ACE2 can be inhibited, viruses cannot enter human cells, and so the protective effect against COVID-19 can be expected.

Figures courtesy of Kyushu University: https://kyodonewsprwire.jp/prwfile/release/M106468/202102241391/_prw_PI3fl_ZgqrfeqJ.jpg

Originally, fucoidan is a high-molecular-weight polysaccharide, but HORIUCHI L-FUCOIDAN is a low-molecular-weight fucoidan which is composed of 500 or less molecular weight by the company's original technique. To evaluate whether fucoidan inhibits the binding of ACE2-virus spike protein, a kit containing ACE2 and coronavirus spike protein was used. L-FUCOIDAN or H-FUCOIDAN (high molecular weight) was incubated together with ACE2 and virus spike protein and the binding inhibition activity was measured.

L-FUCOIDAN showed approximately 100% ACE2-virus spike protein binding inhibition activity at 1.15 mg/mL (left side of the figure below). On the other hand, H-FUCOIDAN (high molecular weight) showed about 20 to 30% of binding inhibition activity in all the tested concentrations. It did not show as much inhibition activity as L-FUCOIDAN (right side of the figure below).

Figures: https://kyodonewsprwire.jp/prwfile/release/M106468/202102241391/_prw_PI2fl_xq4Wd4gE.jpg

*Data courtesy of Kyushu University.

This suggests that HORIUCHI L-FUCOIDAN can be expected to have a preventive effect against COVID-19.

Cision View original content:http://www.prnewswire.com/news-releases/kyushu-university-confirms-horiuchi-l-fucoidan-inhibits-binding-between-ace2-and-virus-spike-protein-derived-from-covid-19-301236198.html

SOURCE FCC Horiuchi Co., Ltd.

Copyright CNW Group 2021

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).